Mini robots from Bionaut Labs provide precise medication29. November 2022
Mini robots from Bionaut Labs provide precise medication
San Francisco, Nov. 29, 2022
Bionaut Labs has received $43.2 million for its microscopic robots that deliver medication to specific areas of the human body.
The startup was founded by robotics engineers Michael Shpigelmacher and Aviad Maizels, who also co-founded PrimeSense, a 3D sensor company acquired by Apple in 2013 for its Face ID technology.
The Bionaut robots rely on a drive controlled by a magnetic field to navigate tissues and blood vessels in the human body.
The robots can breach the blood-brain barrier to deliver specific therapies, such as drugs and chemotherapy, to the human midbrain more precisely and with fewer side effects than systemically administered drugs.
The company says it is developing solutions for the treatment of Parkinson’s disease, Huntington’s disease, hydrocephalus and other central nervous system disorders.
Bionaut plans to use the new funding to further develop programs for malignant glioma brain tumors and Dandy-Walker syndrome.
The Los Angeles startup, which stepped out of stealth mode last March, has now raised $63.2 million.